News

Healthy Returns: AstraZeneca, Pfizer, Gilead and other drugmakers release promising cancer drug data at ASCO
Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, ...
Daiichi Sankyo, AstraZeneca Announce Promising DATROWAY Combination Data in NSCLC
Daiichi Sankyo Company Limited (OTC:DSNKY) and AstraZeneca (NASDAQ:AZN) announced promising results from 3 clinical trials: ...
Applied Clinical Trials Online1d
AstraZeneca and Daiichi Sankyo Share Positive Data From Phase III DESTINY-Breast09 Trial of Enhertu Plus Pertuzumab
In the DESTINY-Breast09 study, Enhertu (fam-trastuzumab deruxtecan-nxki) plus pertuzumab reduced the risk of disease ...
pharmaphorum6d
MSD and Daiichi Sankyo pull HER3-DXd's FDA filing
A year ago, MSD and Daiichi Sankyo's HER3-targeting antibody-drug conjugate patritumab deruxtecan (HER3-DXd) was rejected by ...
DATROWAY® Continues to Show Promising Tumor Responses as Part of Combination Regimens in Patients with Early and Advanced Non-Small Cell Lung Ca…
Results from three trials continue to demonstrate the potential of DATROWAY® (datopotamab deruxtecan) in combination with ...
pharmaphorum1d
ASCO 25: Enhertu bids for earlier use in HER2+ breast cancer
The DESTINY-Breast09 study, reported at ASCO, compared antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) and ...
BioPharma Dive4d
At ASCO, Enhertu cements growing role in stomach cancer care
AstraZeneca and Daiichi Sankyo’s drug extended survival by 30% compared to a widely used regimen, further establishing its ...
STAT4d
At ASCO 2025, attendees see reason for hope, despite worries
The BREAKWATER study enrolled patients with newly diagnosed colon cancer that harbors a mutation called BRAF 600E that makes ...
BioPharma Dive2d
Enhertu potential broadens as new data point to frontline breast cancer role
Study results unveiled at ASCO show combining Enhertu with Perjeta can significantly delay tumor growth versus a regimen that ...
STAT2d
Enhertu, used as first option, stalled tumors for more than a year in women with breast cancer, study finds
The cancer drug Enhertu stalled the growth of tumors by well over a year in a group of women with a type of metastatic but ...
Nasdaq4d
AZN And Daiichi Sankyo's ENHERTU Shows Significant Survival Benefit In Phase 3 Gastric Cancer Trial
(RTTNews) - AstraZeneca (AZN, AZN.L) and Daiichi Sankyo (DSKYF.PK) announced that positive results from the DESTINY-Gastric04 phase 3 trial showed ENHERTU (trastuzumab deruxtecan) demonstrated a ...